The aim of the present study is to evaluate the efficacy of L carnosine on ADHD in children and adolescents through a double-blind, randomized, controlled trial. 50 outpatients, including 6-17 years old who clearly meet the DSM-5 diagnostic criteria for ADHD( based on duiagnosis of a child psychiatrist) will be randomly assigned to receive L carnosine tablets (400mg BID) and methylphenidate (0.5 to 1.5 mg per day) or methylphenidate (0.5 to 1.5 mg per day) and placebo for 8 weeks. The primary outcome measure is the Teacher and Parent ADHD Rating Scale. Patients will be assessed by a child psychiatrist at baseline, 28 and 56 days after the medication started.
General information
Acronym
IRCT registration information
IRCT registration number:IRCT201601031556N84
Registration date:2016-01-04, 1394/10/14
Registration timing:prospective
Last update:
Update count:0
Registration date
2016-01-04, 1394/10/14
Registrant information
Name
Shahin Akhondzadeh
Name of organization / entity
Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 5541 2222
Email address
s.akhond@sina.tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Tehran University of Medical Sciences
Expected recruitment start date
2016-01-21, 1394/11/01
Expected recruitment end date
2017-07-23, 1396/05/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
L Carnosine added to ritaline in the treatment of ADHD: A double blind and placebo controlled trial
Public title
L Carnosine added to risperidone in the treatment of ADHD: A double blind and placebo controlled trial
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: diagnosis of ADHD based on DSM-5; age between 6-17 years old.
Exclusion criteria: mental retardation; receiving of L carnosine during the last 3 weeks; presence of any psychiatric disorders except for ODD; history of allergy to L carnosine or Ritaline; presence of any medical problem including cardiovascular diseases; presence of uncontrolled seizures; systolic blood pressure more than 120 mm Hg; resting pulse rate less than 60/minute or more than 115/minute; receiving any supplement or medication for ADHD.
Age
From 6 years old to 17 years old
Gender
Both
Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size:
50
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics Committee of Tehran University of Medical Sciences
Street address
Keshvarz Blvd
City
Tehran
Postal code
Approval date
2015-12-22, 1394/10/01
Ethics committee reference number
IR.TUMS.REC.1394.1290
Health conditions studied
1
Description of health condition studied
Disturbance of activity and attention
ICD-10 code
F90.0
ICD-10 code description
Disturbance of activity and attention
Primary outcomes
1
Description
Severity of ADHD
Timepoint
Week 0 (before treatment) and Weeks 4 and 8 after treatment
Method of measurement
Teacher and Parent ADHD Rating Scale
Secondary outcomes
empty
Intervention groups
1
Description
Tablet L- carnosine 400 mg BID and Ritaline 0.5 to 1.5 mg per day as intervention group for 8 weeks
Category
Treatment - Drugs
2
Description
Ritaline 0.5 to 1.5 mg per day and placebo as control group for 8 weeks
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
Roozbeh Hospital
Full name of responsible person
Dr. Shahin Akhondzadeh
Street address
South Kargar Sreeet, Roozbeh Hospital
City
Tehran
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr Masoud Yunesian
Street address
Tehran University of Medical Sciences, Keshvarz Blvd
City
Tehran
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty
Person responsible for general inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Kargar street; Roozbeh Hospital
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
S.akhond@sina.tums.ac.ir
Web page address
Person responsible for scientific inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Kargar Street; Roozbeh Hospital,
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
S.akhond@sina.tums.ac.ir
Web page address
Person responsible for updating data
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
South Karegar street; Roozbeh Hospital
City
Tehran
Postal code
Phone
+98 21 5541 2222
Fax
Email
S.akhond@sina.tums.ac.ir
Web page address
Sharing plan
Deidentified Individual Participant Data Set (IPD)